Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APLD-2304 is a preclinical-stage, second-generation blue light cystoscope developed for the diagnosis and operation of non-muscle invasive bladder cancer (NMIBC). It is being advanced by Asieris Pharmaceuticals as part of their Drug Device Combination (DDC) platform, which integrates local drug delivery with device-based diagnostic and therapeutic technologies. The DDC platform leverages targeted fluorescent probes and endoscopic imaging to improve diagnostic accuracy and treatment efficiency while minimizing systemic exposure. APLD-2304 aims to enhance early detection and minimally invasive management of NMIBC by providing improved visualization during cystoscopy procedures[2][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APLD-2304.